论文部分内容阅读
最近,大系列的以医院为基础的研究报道,SCLC占所有肺恶性上皮细胞肿瘤的13～28%。在美国,估计 SCLC 的年发生率为20000～42000例,死亡率为87%。然在过去10年中,局限性疾病长期存活(2年)者仅占15%,播散性5%,治疗并无明显进展。据目前多数报道表明,燕麦细胞型和中间细胞型之间的临床表现、疗效和存活期并无差别;而小细胞与大细胞混合型(据 WHO 分类为中间细胞型的小亚型)病人与纯 SCLC 比较,表现为疗效较差,且预后
Recently, a large series of hospital-based studies reported that SCLC accounted for 13-28% of all malignant lung epithelial cell tumors. In the United States, the annual incidence of SCLC is estimated to be 20,000 to 42,000 and the mortality rate is 87%. However, in the past 10 years, the long-term survival of localized diseases (2 years) accounted for only 15%, spread 5%, and no significant progress in treatment. According to most current reports, there is no difference in clinical manifestations, efficacy, and survival between oat cell types and intermediate cell types; patients with small and large cells (small subtypes classified as intermediate cells according to WHO) are Comparison of pure SCLC shows poor efficacy and prognosis